Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer

Stopped early · Phase 2

Conditions studied: Small Cell Lung Cancer

In brief

Patients with relapsed or chemotherapy-refractory SCLC have a dismal prognosis. Unfortunately, available treatments result in few durable responses. Pemetrexed is a well-tolerated agent, which is active in NSCLC. Since chemotherapy agents, which are active in NSCLC, are usually also active in SCLC, this trial will examine the efficacy and activity of pemetrexed in this palliative setting

Key facts

Study ID

NCT00216216

Run by

Hoosier Cancer Research Network

People needed

43

Starts

2005-01-01

Expected to finish

2005-10-01

Last updated by the study team

2011-05-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histological or cytological proof of neuroendocrine cancers (including small cell cancers of any site [including lung] or poorly differentiated neuroendocrine cancers of the lung with (unidimensionally) measurable disease as per the RECIST criteria
• Chemoresistant or chemosensitive disease
• Patients must have received treatment with at least one but not more than 2 prior chemotherapy regimens, including one regimen containing a platinum agent
• Radiation therapy must have completed their radiation at least 14 days prior to being registered for protocol therapy, and toxicities due to radiation must have recovered to < grade 1 or baseline prior to registration
• Negative pregnancy test

You may not qualify if…

• No clinically significant infections as judged by the treating investigator
• No symptomatic CNS metastasis
• No radiation to > 25% of the marrow containing spaces
• No previous treatment with pemetrexed
• No uncontrolled pleural effusions
• No current breastfeeding

Where it is running

• Helen F. Graham Cancer Center — Newark, Delaware, United States
• Medical & Surgical Specialists, LLC — Galesburg, Illinois, United States
• Elkhart Clinic — Elkhart, Indiana, United States
• Oncology Hematology Associates of SW Indiana — Evansville, Indiana, United States
• Fort Wayne Oncology & Hematology, Inc — Fort Wayne, Indiana, United States
• Center for Cancer Care at Goshen Health System — Goshen, Indiana, United States
• Indiana University Cancer Center — Indianapolis, Indiana, United States
• Community Regional Cancer Center — Indianapolis, Indiana, United States
• Arnett Cancer Care — Lafayette, Indiana, United States
• Medical Consultants, P.C. — Muncie, Indiana, United States
• Center for Cancer Care, Inc., P.C. — New Albany, Indiana, United States
• Northern Indiana Cancer Research Consortium — South Bend, Indiana, United States
• Northern Indiana Oncology Associates — South Bend, Indiana, United States
• AP&S Clinic — Terre Haute, Indiana, United States
• Siteman Cancer Center — St Louis, Missouri, United States
• Methodist Cancer Center — Omaha, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.